Novel Evidence-Based Systemic Lupus Erythematosus Responder Index

OBJECTIVE: To describe a new systemic lupus erythematosus (SLE) Responder Index (SRI) based on the belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials. METHODS: Data from a 449-patient randomized, double-blind, placebo-controlled study of 3 doses of belimumab (1...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Furie, Richard A., Petri, Michelle A., Wallace, Daniel J., Ginzler, Ellen M., Merrill, Joan T., Stohl, William, Chatham, W. Winn, Strand, Vibeke, Weinstein, Arthur, Chevrier, Marc R., Zhong, John, Freimuth, William W.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2748175/
https://ncbi.nlm.nih.gov/pubmed/19714615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.24698
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars